vs
Mind Medicine (MindMed) Inc.（DFTX）与MediWound Ltd.（MDWD）财务数据对比。点击上方公司名可切换其他公司
MediWound Ltd.的季度营收约是Mind Medicine (MindMed) Inc.的6.3倍（$5.7M vs $906.0K）。MediWound Ltd.净利率更高（-233.3% vs -2634.0%，领先2400.7%）。MediWound Ltd.同比增速更快（12.7% vs -16.1%）
Definium Therapeutics（前称MindMed）是一家总部位于纽约的生物技术企业，专注于致幻剂及更广泛的精神可塑性药物的临床与治疗应用开发，在中枢神经药物研发领域深耕相关创新疗法的落地潜力。
MediWound Ltd.是一家聚焦烧伤护理、慢性创面治疗及软组织修复领域的生物制药企业，研发、生产及销售创新创面护理产品，主要面向北美、欧洲及亚洲市场的医院、医疗机构及患者提供服务。
DFTX vs MDWD — 直观对比
营收规模更大
MDWD
是对方的6.3倍
$906.0K
营收增速更快
MDWD
高出28.9%
-16.1%
净利率更高
MDWD
高出2400.7%
-2634.0%
损益表 — Q4 2023 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $906.0K | $5.7M |
| 净利润 | $-23.9M | $-13.3M |
| 毛利率 | — | 23.5% |
| 营业利润率 | -2450.8% | -100.1% |
| 净利率 | -2634.0% | -233.3% |
| 营收同比 | -16.1% | 12.7% |
| 净利润同比 | -386.7% | -111.2% |
| 每股收益（稀释后） | $-0.58 | $-1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DFTXMDWD
| Q2 25 | — | $5.7M | ||
| Q2 24 | — | $5.1M | ||
| Q4 23 | $906.0K | — | ||
| Q3 23 | $1.2M | — | ||
| Q2 23 | $1.3M | $4.8M | ||
| Q1 23 | $1.3M | — | ||
| Q4 22 | $1.1M | — | ||
| Q3 22 | $360.0K | — |
净利润DFTXMDWD
| Q2 25 | — | $-13.3M | ||
| Q2 24 | — | $-6.3M | ||
| Q4 23 | $-23.9M | — | ||
| Q3 23 | $-17.9M | — | ||
| Q2 23 | $-29.1M | $916.0K | ||
| Q1 23 | $-24.8M | — | ||
| Q4 22 | $-4.9M | — | ||
| Q3 22 | $-16.5M | — |
毛利率DFTXMDWD
| Q2 25 | — | 23.5% | ||
| Q2 24 | — | 8.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 23.8% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
营业利润率DFTXMDWD
| Q2 25 | — | -100.1% | ||
| Q2 24 | — | -88.6% | ||
| Q4 23 | -2450.8% | — | ||
| Q3 23 | -1858.6% | — | ||
| Q2 23 | -2226.1% | -84.0% | ||
| Q1 23 | -1624.8% | — | ||
| Q4 22 | -1287.0% | — | ||
| Q3 22 | -4717.5% | — |
净利率DFTXMDWD
| Q2 25 | — | -233.3% | ||
| Q2 24 | — | -124.5% | ||
| Q4 23 | -2634.0% | — | ||
| Q3 23 | -1541.1% | — | ||
| Q2 23 | -2222.0% | 19.2% | ||
| Q1 23 | -1932.6% | — | ||
| Q4 22 | -454.0% | — | ||
| Q3 22 | -4579.2% | — |
每股收益（稀释后）DFTXMDWD
| Q2 25 | — | $-1.23 | ||
| Q2 24 | — | $-0.68 | ||
| Q4 23 | $-0.58 | — | ||
| Q3 23 | $-0.45 | — | ||
| Q2 23 | $-0.76 | $0.10 | ||
| Q1 23 | $-0.65 | — | ||
| Q4 22 | $-0.02 | — | ||
| Q3 22 | $-0.56 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $99.7M | $1.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $78.1M | $20.1M |
| 总资产 | $124.5M | $67.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DFTXMDWD
| Q2 25 | — | $1.1M | ||
| Q2 24 | — | $3.8M | ||
| Q4 23 | $99.7M | — | ||
| Q3 23 | $117.7M | — | ||
| Q2 23 | $116.9M | $19.2M | ||
| Q1 23 | $129.4M | — | ||
| Q4 22 | $142.1M | — | ||
| Q3 22 | $154.5M | — |
股东权益DFTXMDWD
| Q2 25 | — | $20.1M | ||
| Q2 24 | — | $17.9M | ||
| Q4 23 | $78.1M | — | ||
| Q3 23 | $96.0M | — | ||
| Q2 23 | $106.0M | $34.9M | ||
| Q1 23 | $130.3M | — | ||
| Q4 22 | $150.9M | — | ||
| Q3 22 | $153.6M | — |
总资产DFTXMDWD
| Q2 25 | — | $67.0M | ||
| Q2 24 | — | $57.3M | ||
| Q4 23 | $124.5M | — | ||
| Q3 23 | $141.6M | — | ||
| Q2 23 | $142.1M | $64.4M | ||
| Q1 23 | $155.5M | — | ||
| Q4 22 | $170.0M | — | ||
| Q3 22 | $180.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.6M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DFTXMDWD
| Q2 25 | — | $-5.8M | ||
| Q2 24 | — | $-3.6M | ||
| Q4 23 | $-20.6M | — | ||
| Q3 23 | $-16.6M | — | ||
| Q2 23 | $-13.8M | $-5.3M | ||
| Q1 23 | $-13.3M | — | ||
| Q4 22 | $-12.8M | — | ||
| Q3 22 | $-9.3M | — |
现金转化率DFTXMDWD
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -5.73× | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
